496 related articles for article (PubMed ID: 27673363)
21. Highly-accurate metabolomic detection of early-stage ovarian cancer.
Gaul DA; Mezencev R; Long TQ; Jones CM; Benigno BB; Gray A; Fernández FM; McDonald JF
Sci Rep; 2015 Nov; 5():16351. PubMed ID: 26573008
[TBL] [Abstract][Full Text] [Related]
22. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial.
Hayes RB; Reding D; Kopp W; Subar AF; Bhat N; Rothman N; Caporaso N; Ziegler RG; Johnson CC; Weissfeld JL; Hoover RN; Hartge P; Palace C; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):349S-355S. PubMed ID: 11189687
[TBL] [Abstract][Full Text] [Related]
23. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
[TBL] [Abstract][Full Text] [Related]
24. Focused Decision Support: a Data Mining Tool to Query the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dataset and Guide Screening Management for the Individual Patient.
Sharma A; Hostetter J; Morrison J; Wang K; Siegel E
J Digit Imaging; 2016 Apr; 29(2):160-4. PubMed ID: 26385814
[TBL] [Abstract][Full Text] [Related]
25. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
[TBL] [Abstract][Full Text] [Related]
26. Overall mortality in men and women in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Pinsky PF; Miller EA; Zhu CS; Prorok PC
J Med Screen; 2019 Sep; 26(3):127-134. PubMed ID: 30943843
[No Abstract] [Full Text] [Related]
27. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
28. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
Braillon A; Dubois G
J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
[No Abstract] [Full Text] [Related]
29. Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.
Shikany JM; Flood AP; Kitahara CM; Hsing AW; Meyer TE; Willcox BJ; Redden DT; Ziegler RG
Cancer Causes Control; 2011 Jul; 22(7):995-1002. PubMed ID: 21553078
[TBL] [Abstract][Full Text] [Related]
30. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
[TBL] [Abstract][Full Text] [Related]
31. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Luhn P; Dallal CM; Weiss JM; Black A; Huang WY; Lacey JV; Hayes RB; Stanczyk FZ; Wentzensen N; Brinton LA
Cancer Epidemiol Biomarkers Prev; 2013 Jul; 22(7):1304-12. PubMed ID: 23696194
[TBL] [Abstract][Full Text] [Related]
32. Specificity of metabolic colorectal cancer biomarkers in serum through effect size.
Di Giovanni N; Meuwis MA; Louis E; Focant JF
Metabolomics; 2020 Aug; 16(8):88. PubMed ID: 32789702
[TBL] [Abstract][Full Text] [Related]
33. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial.
Peters U; Leitzmann MF; Chatterjee N; Wang Y; Albanes D; Gelmann EP; Friesen MD; Riboli E; Hayes RB
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):962-8. PubMed ID: 17507623
[TBL] [Abstract][Full Text] [Related]
34. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
35. Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.
O'Grady TJ; Kitahara CM; DiRienzo AG; Boscoe FP; Gates MA
PLoS One; 2014; 9(9):e106880. PubMed ID: 25192282
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of blood metabolites associated with colorectal cancer risk.
Shu X; Xiang YB; Rothman N; Yu D; Li HL; Yang G; Cai H; Ma X; Lan Q; Gao YT; Jia W; Shu XO; Zheng W
Int J Cancer; 2018 Aug; 143(3):527-534. PubMed ID: 29479691
[TBL] [Abstract][Full Text] [Related]
37. Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.
Shiels MS; Katki HA; Hildesheim A; Pfeiffer RM; Engels EA; Williams M; Kemp TJ; Caporaso NE; Pinto LA; Chaturvedi AK
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26220734
[TBL] [Abstract][Full Text] [Related]
38. The metabolomic detection of lung cancer biomarkers in sputum.
Cameron SJ; Lewis KE; Beckmann M; Allison GG; Ghosal R; Lewis PD; Mur LA
Lung Cancer; 2016 Apr; 94():88-95. PubMed ID: 26973212
[TBL] [Abstract][Full Text] [Related]
39. Metabolomic serum profiling detects early-stage high-grade serous ovarian cancer in a mouse model.
Jones CM; Monge ME; Kim J; Matzuk MM; Fernández FM
J Proteome Res; 2015 Feb; 14(2):917-27. PubMed ID: 25567202
[TBL] [Abstract][Full Text] [Related]
40. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
